The experience of using triple targeted therapy (elexacaftor/ tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes
- 17 April 2026
- journal article
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (2)
Abstract
This article discusses the clinical experience of using triple targeted therapy (elexacaftor/tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes. The description includes details on the diagnostic process, the features of the disease course, and treatment approaches. In addition, the work pays special attention to the use of targeted drugs, as well as the need for an integrated approach to managing the condition of patients with combined disorders. To date, there has been insufficient research on the efficacy of the drug elexacaftor/ tezacaftor/ivacaftor and its effects on patients with comorbid conditions, particularly those suffering from cystic fibrosis-related diabetes. The aim was to highlight modern research on this topic and to assess the effect of triple targeted therapy on the clinical manifestations of the disease. Results. The patient showed significant improvement in the functional state of the lungs, control of blood glucose levels, and overall quality of life. Conclusion. The article summarizes the importance of an individualized approach to therapy that considers both genetic and metabolic aspects of the disease. The conclusion emphasizes the importance of early, timely initiation of treatment to achieve optimal results and improve the prognosis of long-term life in patients with cystic fibrosis and related complications.Keywords
This publication has 16 references indexed in Scilit:
- Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosisClinical Nutrition ESPEN, 2023
- New Concepts in the Pathogenesis of Cystic Fibrosis–Related DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2022
- Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patientsJournal of Cystic Fibrosis, 2020
- Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registriesJournal of Cystic Fibrosis, 2020
- Survival in a bad neighborhood: pancreatic islets in cystic fibrosisJournal of Endocrinology, 2019
- Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftorJournal of Cystic Fibrosis, 2019
- ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescentsPediatric Diabetes, 2018
- Cystic fibrosis–related diabetes is caused by islet loss and inflammationJCI Insight, 2018
- CFTR Influences Beta Cell Function and Insulin Secretion Through Non-Cell Autonomous Exocrine-Derived FactorsEndocrinology, 2017
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent MannerJournal of Biological Chemistry, 2012